Bergen, Norway, 28 May 2024: Reference is made to the stock exchange
announcement published by BerGenBio ASA (the "Company") on 23 May 2023,
regarding the Company's annual general meeting resolving a reverse share split
of the Company's shares. Key information related to the reverse share split is
set out below:

  · Reverse split ratio: 100:1, i.e. one hundred (100) old shares give one (1)
new share
  · Date on which the corporate action was made public: 30 April 2024
  · Date of approval: 23 May 2024 (AGM)
  · Last day including right: 29 May 2024 (trading inclusive right of reverse
split)
  · Ex-date: 30 May 2024 (trading exclusive right of reverse split)
  · Record date: 31 May 2024
  · New number of shares outstanding after reverse share split: 39,087,116

In connection with the reverse share split, the Company's shares will be
transferred to a new ISIN.

Please note the following key information for the change of ISIN:

  · Issuer: BerGenBio ASA
  · Previous ISIN: NO 001 0650013
  · New ISIN: NO 001 3251173
  · Date of ISIN change: 30 May 2024

For further information, please contact:

Martin Olin, CEO, BerGenBio ASA
ir@bergenbio.no

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit www.bergenbio.com.

This information is published in accordance with the requirements of the
Continuing Obligations pursuant to Oslo Rule Book II.